At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed May 11, 2026 at 16:05 ET
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue biotech). Net loss narrowed to $20.0M from $56.2M a year ago due to lower R&D spend after terminating bexotegrast. The company highlighted early clinical progress for PLN-101095 in ICI-refractory tumors, including a complete response and two partial responses, but the EPS miss and absence of near-term catalysts cap the upside for a $76M market cap stock.
- Q1 2026 EPS of -$0.38 missed consensus of -$0.36 (-6.2% miss)
- Revenue was $0 (pre-revenue clinical-stage biotech)
- Net loss narrowed to $20.0M from $56.2M YoY, driven by lower R&D spend after bexotegrast termination
- Cash, cash equivalents and short-term investments of $172.4M expected to fund operations into H2 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access